Lipodystrophy Syndromes

Dermatologic Clinics

Volumn 26, Issue 4, 2008, Pages 569-578

  Herranz, Pedro ^a   de Lucas, Raul ^a   Pérez España, Luis ^a   Mayor, Matias ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

AIDS; HIV infection; Lipoatrophy; Lipodystrophy

Indexed keywords

ABACAVIR; EFAVIRENZ; GROWTH HORMONE; METFORMIN; NEVIRAPINE; PIOGLITAZONE; POLYLACTIC ACID; RECOMBINANT LEPTIN; ROSIGLITAZONE; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONGENITAL GENERALIZED LIPODYSTROPHY; DIABETES MELLITUS; FAMILIAL PARTIAL LIPODYSTROPHY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPOATROPHY; LIPODYSTROPHY; LIVER DISEASE; PRIORITY JOURNAL; REVIEW;

ADIPOSE TISSUE; DIAGNOSIS, DIFFERENTIAL; HUMANS; LIPODYSTROPHY; SYNDROME;

EID: 51349164346     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2008.05.004     Document Type: Review

References (81)

1. Garg A. Lipodystrophies. Am J Med 108 (2000) 143-152
2. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 350 (2004) 1220-1234
3. Ganda O.P. Lipoatrophy, lipodistrophy and insulin resistance. Ann Intern Med 133 (2000) 304-306
4. Misra A., Peethambaram A., and Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine 83 (2004) 18-34
5. Berardinelli W. An undiagnosed endocrinometabolic syndrome: a report of two cases. J Clin Endocrinol Metab 14 (1954) 193-204
6. Seip M. Lipodystrophy and gigantism with associated endocrine manifestations: a new diencephalic syndrome?. Acta Paediatr 48 (1959) 555-574
7. Garg A., Fleckenstein J.L., Peshock R.M., et al. Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab 75 (1992) 358-361
8. Seip M., and Trygstad O. Generalized lipodistrophy, congenital and acquired (lipoatrophy). Acta Paediatr 413 Suppl (1996) 2-28
9. Garg A., Chandalia M., and Vuitch F. Severe islet amyloidosis in congenital generalized lipodystrophy. Diabetes Care 19 (1996) 28-31
10. Simha V., and Garg A. Phenotipic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab 88 (2003) 5433-5437
11. Agarwal A.K., Arioglu E., De Almeida S., et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 31 (2002) 21-23
12. Fang Y.M., Vilella-Bach M., Bachmann R., et al. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294 (2001) 1942-1945
13. Agarwal A.K., Simha V., Oral E.A., et al. Phenotypic and genetic heterogeneity in congenital generalized lypodistrophy. J Clin Endocrinol Metab 88 (2003) 4840-4847
14. Dunnigan M.G., Cochrane M.A., Kelly A., et al. Familial lipoatrophic diabetes with dominant transmission: a new syndrome. Q J Med 43 (1974) 33-48
15. Speckman R.A., Garg A., and Du F. Mutational and haplotype analysis of families with familial partial lipodystrophy (Duningan variety) reveal recurrent missense mutations in the globular C-terminal of lamin A/C. Am J Hum Genet 66 (2000) 1192-1198
16. Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 85 (2000) 1776-1782
17. Peters J.M., Barnes R., Bennet L., et al. Localization for the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nat Genet 18 (1998) 292-295
18. Cao H., and Hegele R.A. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 9 (2000) 109-112
19. Vigouroux C., Magre J., Vantyghem M.C., et al. Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes 49 (2000) 1958-1962
20. Van der Kooi A.J., Bonne G., Eymard B., et al. Lamin A/C mutations with lipodystrophy, cardiac abnormalities and muscular dystrophy. Neurology 59 (2002) 620-623
21. Agarwal A.K., and Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87 (2002) 408-411
22. Herbst K.L., Tannock L.R., Deeb S.S., et al. Kobberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 26 (2003) 1819-1824
23. Simha V., and Garg A. Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associate with mandibuloacral dysplasia. J Clin Endocrinol Metab 87 (2002) 776-785
24. Novelli G., Muchir A., Sangiuolo F., et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 71 (2002) 426-431
25. Misra A., and Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine 82 (2003) 129-146
26. Font J., Herrero C., Bosch X., et al. Systemic lupus erythematosus in a patient with partial lipodystrophy. J Am Acad Dermatol 22 (1990) 337-340
27. Huermer C., Kitson H., Malleson P.N., et al. Lipodystrophyin patients with juvenile dermatomyositis: evaluation of clinical and metabolic abnormalities. J Rheumatol 28 (2001) 610-615
28. Quecedo E., Febrer I., Serrano G., et al. Partial lipodystrophy associated with juvenile dermatomyositis. Arch Dermatol 127 (1991) 1846-1847
29. Porter W.M., ÓGorman-Lalor O., Lane R.J.M., et al. Barraquer-Simmonds lipodystrophy, Raynaud phenomenon and cutaneous vasculitis. Clin Exp Dermatol 25 (2000) 277-280
30. Perrot H. Lipodystrophy de Barraquer et Simmonds anomalies complémentaires et vasculite leucocytoclasique cutanée. Ann Dermatol Venereol 114 (1987) 1083-1091
31. Requena C., Navarro M.A., Febrer I., et al. Barraquer-Simmonds lipodystrophy associated with antiphospholipid syndrome. J Am Acad Dermatol 49 (2003) 768-769
32. Hegele R.A. Molecular basis of partial lipodystrophy and prospects for therapy. Trends Mol Med 7 (2001) 121-126
33. Williams D.G., Bartlett A., and Duffus P. Identification of nephritic factor as an immunoglobulin. Clin Exp Immunol 33 (1978) 425-429
34. Mathieson P.W., and Peters K. Are nephritic factors nephrithogenic?. Am J Kidney Dis 24 (1994) 964-966
35. Palella Jr. F.J., Delaney K., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced HIV infection: outpatient study investigators. N Engl J Med 338 (1998) 853-860
36. Carr A., and Cooper D.A. Adverse effects of antiretroviral therapy. Lancet 356 (2000) 1423-1430
37. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12 (1998) 51-58
38. Duran S., Savs M., Spire B., et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodistrophy. AIDS 15 (2001) 2441-2444
39. Ammassari A., Murri R., Pezzotti P., et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 8 (2001) 445-449
40. Hadigan C., Meigs J., Corcoran C., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32 (2001) 130-139
41. Yarasheki K.E., Tebas P., Sigmund C., et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr Hum Retrovirol 21 (1999) 209-216
42. Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 337-343
43. Dank J.P., and Colven R. Protease inhibitor-associated angiolipomatosis. J Am Acad Dermatol 42 (2000) 129-131
44. Gougeon M.L., Penicaud L., Fromenty B., et al. Adipocyte targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 9 (2004) 161-177
45. Brinkman K., Smeitink J.A., Romjin J., et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354 (1999) 1112-1125
46. Liechtenstein K.A., Delaney K.M., Armon C., et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. J Acquir Immune Defic Syndr 32 (2003) 48-56
47. Mallon P., Miller J., Cooper D., et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS 17 (2003) 971-979
48. HIV Lipodistrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361 (2002) 726-735
49. Amassari A., Antinori A., Cozzi-Lepri A., et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 31 Suppl 3 (2002) S140-S144
50. Miller V., Sabin C., Hertogs K., et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14 (2000) 2857-2867
51. James J., Carruthers A., and Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 28 (2002) 979-986
52. Madasseri A., McDermott M.B., and Irvine A.D. Lipoatrophic panniculitis of the ankles. Clin Exp Dermatol 31 (2006) 303-305
53. Kshiteendra K., Mane R.P., and Kavita K. Insulin induced lipoatrophy. Indian J Dermatol Venereol Leprol 69 (2003) 310-311
54. Herold D.A., and Albrecht G. Local lipohypertrophy in insulin treatment. Hautarzt 44 (1993) 40-42
55. Kayikeoglu A., Akyurek M., and Erk Y. Semicircular lipoatrophy after intragluteal injection of benzathine penicillin. J Pediatr 129 (1996) 166-167
56. Haas N., Henz B.M., Bunikowski R., et al. Semicircular lipoatrophy in a child with systemic lupus erythematosus after subcutaneous injections of methotrexate. Pediatr Dermatol 19 (2002) 432-435
57. Gomez-Espejo C., Perez-Bernal A., and Camacho-Martínez F. A new case of semicircular lipoatrophy associated with repeated external microtraumas and review of the literature. J Eur Acad Dermatol Venereol 19 (2005) 459-461
58. Gruber P.C., and Fuller C. Lipoatrophy semicircularis induced by trauma. Clin Exp Dermatol 26 (2001) 269-271
59. Rongioletti F., and Rebora A. Annular and semicircular lipoatrophies: report of three cases and review of the literature. J Am Acad Dermatol 20 (1989) 433-436
60. Imamura S., Yamada M., and Ikeda T. Lipodystrophia centrifugalis abdominalis infantilis. Arch Dermatol 104 (1971) 291-298
61. Valantin M.A., Aubron-Olivier C., Ghosn J., et al. Polylactic acid implants (Newfill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 17 (2003) 2471-2477
62. Brown S., Moyle G.C., Lysakova L., et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 5 (2004) 82-87
63. Friedman P.M., Skover G.R., Payonk G., et al. 3D in-vivo optical skin imaging for topographical quantitative assessment of non-ablative laser technology. Dermatol Surg 28 (2002) 199-204
64. Ascher B., Coleman S., Alster T., et al. Full scope of effect of facial lipoatrophy: a framework of disease understanding. Dermatol Surg 32 8 (2006) 1058-1069
65. Marchesini G., Brizi M., Bianchi G., et al. Metformin in non-alcoholic steatohepatitis. Lancet 358 (2001) 893-894
66. Nestler J.E., Jabubowicz D.J., Evans W.S., et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338 (1998) 1876-1880
67. Ponce-de-Leon S., Iglesias M., Ceballos J., et al. Liposuction for protease-inhibitor associated lipodystrophy. Lancet 353 (1999) 1244
68. Carr A., Workman C., Carey D., et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363 (2004) 429-438
69. Martínez E., Domingo P., Ribera E., et al. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antivir Ther 8 (2003) 403-410
70. Roubenoff R., Weiss L., McDermott A., et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat distribution. AIDS 13 (1999) 1373-1375
71. Martinez E., Arnaiz J., Podzamczer D., et al. Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with HIV infection. N Eng J Med 349 (2002) 1036-1046
72. Milinkovic A, Lopez S, Vidal S, et al. A randomized open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudin [abstract 857]. 12th Annual Conference on Retroviruses and Opportunistic Infections. Boston, February 22-25, 2005.
73. Negredo E., Moltó J., Burger D., et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). J Acquir Immune Defic Syndr 38 (2005) 47-52
74. Maggiolo F., Ripamonti D., Gregis G., et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 18 (2004) 439-446
75. Serra-Renom J.M., Milinkovic A., Martinez E., et al. Treatment of facial fat atrophy related to treatment with protease inhibitors by autologous fat injection in patients with human immunodeficiency virus infection. Plast Reconstr Surg 114 (2004) 551-555
76. Mest D.R., and Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg 32 (2006) 1336-1345
77. Burgess C.M., and Quiroga R.M. Assessment of the safety and efficacy of poly-L-lactic for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 52 (2005) 233-239
78. Treacy P.J., and Goldberg D.J. Use of a biopolymer polyalkylimide filler for facial lipodistrophy in HIV-positive patients undergoing treatment with antiretroviral drugs. Dermatol Surg 32 (2006) 804-808
79. Orentreich D. Liquid injectable silicone: techniques for soft tissue augmentation. Clin Plast Surg 27 (2000) 595-612
80. Roy D., Sadick N., and Mangat D. Clinical trial of a novel filler material for soft tissue augmentation of the face containing synthetic calcium hydroxylapatite microspheres. Dermatol Surg 32 (2006) 1134-1139
81. Silvers S.L., Eviatar J.A., Echavez M.I., et al. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 118 Suppl (2006) 34S-45S